Manulife bids for full control of China fund JV, lured by $3.8 trln mkt -sources



By Selena Li and Samuel Shen

HONG KONG/SHANGHAI, June 29 (Reuters) - Canada's Manulife Financial Corp MFC.TO moved closer toward taking full control of its funds joint venture in China after regulators there accepted an application for the ownership change, two sources with knowledge of the matter told Reuters.

Manulife, Canada's largest life insurer, is seeking to bolster its presence in China's $3.8 trillion funds market, which grew 27% in 2021 and is forecast by consultancy McKinsey to more than double by 2025.

China's securities regulator officially accepted a recent application from Manulife's asset management arm to increase its stake in the joint venture to 100% from the current 49%, said the sources.

Manulife shares fell 0.2% to C$22.46 at midday in Toronto, compared with a 0.85% decline in the Toronto stock benchmark .GSPTSE .

Manulife Investment Management acquired the stake in Manulife Teda Fund Management in China in 2010 from ABN AMRO bank and teamed up with state-owned Tianjin TEDA International Holding, which owns the remaining 51% equity but is looking to sell it.

The move furthers Manulife's stated goal of expanding both its Asian and asset management units, and its intention to deploy more capital in China.

Foreign companies are jockeying for position as China opens up the financial services sector, from investment banking to insurance, to global competition.

Manulife Investment Management and Manulife Teda Fund Management spokespeople declined to comment.

Since ownership caps for foreign companies in fund management JVs were scrapped in 2019, a growing number of foreign asset managers, including BlackRock BLK.N and Fidelity, have set up operations in China to compete for a share of the country's swelling mutual funds market.

The official acceptance of Manulife's application by the China Securities Regulatory Commission (CSRC) means the Canadian company is "a step closer" to taking full control of the venture, which had around 60 billion yuan ($8.96 billion) in retail fund assets as of March. An approval could come soon, although the timing is unknown, one of the sources said.

A CSRC public disclosure on May 22 shows it had made a decision on whether it would consider a Manulife Teda application to change more than 5% ownership, but does not reveal its decision.

The CSRC did not respond to a request for comment.

HIRING CEO

Besides the fund management joint venture in China, Manulife also has a 51% stake in an insurance joint venture with Sinochem, and has been open about its aspiration to increase its share of that as well.

Manulife's Asia CEO told Reuters earlier this month the regional unit was on track to account for half of the Canadian insurer's core earnings by 2025 despite economic slowdowns and impact of COVID-19 on its key markets.

The change at the fund venture got underway in July last year when Tianjin TEDA put its stake on the block for around $263 million, one of the sources said.

The venture is also in the final stages of tapping the general manager of a rival foreign fund in China to head its operations, one of the sources said.

JPMorgan JPM.N became the first global bank that filed with the Chinese regulator last year to convert its local fund joint venture into a wholly owned business, which has yet to receive regulatory approval.

($1 = 6.6970 Chinese yuan renminbi)
Reporting by Selena Li in Hong Kong and Samuel Shen in Shanghai; Additional reporting by Nichola Saminather; Editing by Sumeet Chatterjee, Muralikumar Anantharaman and Richard Chang

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明